国际生殖健康/计划生育杂志

国际生殖健康/计划生育 ›› 2011, Vol. 30 ›› Issue (4): 302-304.

• 综述 • 上一篇    下一篇

控制性卵巢刺激药物对胎儿安全性的评价

倪 郝,全 松   

  1. 510515 广州，南方医科大学南方医院妇产科生殖医学中心
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2011-07-15 发布日期:2011-07-15
  • 通讯作者: 全 松

Drugs of the Controlled Ovarian Stimulation and Fetal Safety

NI Hao, QUAN Song   

  1. Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
  • Received:1900-01-01 Revised:1900-01-01 Published:2011-07-15 Online:2011-07-15
  • Contact: QUAN Song

PDF (PC)

7156

摘要： 评估不孕症治疗中常用的控制性卵巢刺激（controlled ovarian stimulation， COS）药物对胎儿的安全性极为重要。可利用的数据资料表明，未发现不孕症治疗中常用的COS药物有明显致畸性，并且不会增加出生缺陷率。然而，不孕症本身可能就是形成先天畸形的危险因素之一。综述COS常用药物、药物对胎儿的致畸性及其引起的胎儿畸形的类型。

关键词: 不育, 女（雌）性, 超排卵, 先天畸形, 药物监测, 促性腺素释放激素, 促性腺素类

Abstract: It is very important to evaluate the fetal safety of drugs of the controlled ovarian stimulation (COS) in infertility treatment. The available data suggested that COS drugs did not increase the rate of birth defects. There was not evidence to show that COS drugs had obvious teratogenic effects. In fact, infertility itself may be one of the risk factors for congenital malformation. In this review, we briefly introduced COS drugs, their teratogenic effects on offsprings, as well as malformation types.

Key words: Infertility, female, Superovulation, Congenital abnormalities, Drug monitoring, Gonadotropin?-releasing hormone, Gonadotropins